> CPDR News
CPDR Launches New Interactive Tool
Latest Nomogram Predicting 5- and 10-year Overall Survival for Prostate Cancer (CaP) Patients
March 4, 2005
This week, CPDR launched its latest nomogram predicting 5- and 10-year overall survival for prostate cancer (CaP) patients who have undergone radical prostatectomy followed by a PSA recurrence. This tool demonstrates the importance of PSA doubling time in predicting time to death among CaP patients treated surgically.
The title and abstract of her paper presented in the meeting:
These results were presented in an Abstract at this year's second annual American Society of Clinical Oncology (ASCO) Prostate Cancer Symposium, sponsored by ASCO, the Prostate Cancer Foundation, ASTRO, and the Society for Clinical Oncology (SUO).
The CPDR mission is fulfilled primarily through its three principal programs – the Clinical Research Center, the Basic Science Research Program and the National Multicenter Prostate Cancer Database– and through a robust education and training program that operates out of its Headquarters location, the Clinical Research Center, and the original laboratories at USUHS. CPDR is also committed to patient outreach, primarily through its affiliation with the WRAMC US TOO! organization and through a heavy schedule of health fairs in which it participates.
